Type 2 diabetes drug Invokana (canagliflozin) was the subject of the Canagliflozin Cardiovascular Assessment Study (CANVAS) and the CANVAS renal-end-points trial (CANVAS-R).  While it was recently shown to have significant cardiovascular benefits, it also carries double the risk of lower-limb amputations. In terms of cardiovascular event … [Read more...]